As Covid-19 shot sales dwindle, BioNTech doubles down on cancer vaccines BioNTech is over covid. Or looking past it, at least, planning to invest the company’s pandemic windfall into the development of oncology products.Read more... https://qz.com/as-covid-19-shot-sales-dwindle-biontech-doubles-down-o-1850267976










